Granite Point Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Granite Point Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-5,000	Closed	-$422K	–	76
2019 Q2	$422K	Buy	+5,000	New	+$450K	0.03%	80
2015 Q4	$2.97M	Buy	+90,000	New	+$2.93M	0.44%	11
2015 Q2	–	Sell	-22,000	Closed	-$674K	–	102
2015 Q1	$674K	Hold	22,000	–	–	0.25%	65
2014 Q4	$1.12M	Sell	22,000 -3,000	-12%	-$134K	0.52%	34
2014 Q3	$989K	Hold	25,000	–	–	0.49%	43
2014 Q2	$1.08M	Sell	25,000 -30,000	-55%	-$1.14M	0.74%	26
2014 Q1	$2.2M	Sell	55,000 -5,000	-8%	-$182K	1.57%	16
2013 Q4	$1.64M	Buy	+60,000	New	+$1.45M	0.27%	37

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Granite Point Capital Management's ENTA Position: Q3 2019 in Review

Granite Point Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2019, closing a stake of 5,000 shares — an estimated $422K sold.

Granite Point Capital Management first reported a position in ENTA in Q4 2013 and held it in 8 quarters. The position peaked at $2.97M in Q4 2015. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

Granite Point Capital Management reported no remaining Enanta Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Granite Point Capital Management sold 5,000 Enanta Pharmaceuticals shares in Q3 2019, an estimated $422K.
Granite Point Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 8 quarters.
Granite Point Capital Management's Enanta Pharmaceuticals position peaked at $2.97M in Q4 2015.
176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Granite Point Capital Management's 13F filing for Q3 2019, filed 30 Oct 2019.